Analytical metabolomics-based approaches to pancreatic cancer

TrAC - Trends in Analytical Chemistry

Volumn 55, Issue , 2014, Pages 94-116

  Di Gangi, Iole Maria ^a   Vrhovsek, Urska ^a   Pazienza, Valerio ^b   Mattivi, Fulvio ^a  

^a RESEARCH AND INNOVATION CENTRE   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Analytical method; Biomarker; Extraction; Mass spectrometry; Metabolic profile; Metabolomics; Pancreatic cancer; Pathogenesis; Physiopathology; Sample preparation

Indexed keywords

BIOMARKERS; DISEASES; EXTRACTION; MASS SPECTROMETRY; METABOLISM; METABOLITES; RESEARCH; TUMORS;

ANALYTICAL METHOD; METABOLIC PROFILES; METABOLOMICS; PANCREATIC CANCERS; PATHOGENESIS; PHYSIOPATHOLOGY; SAMPLE PREPARATION;

DIAGNOSIS;

TUMOR MARKER;

BODY FLUID; CANCER RISK; CARBON NUCLEAR MAGNETIC RESONANCE; CARCINOGENESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; ION TRAP MASS SPECTROMETRY; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 84894277045     PISSN: 01659936     EISSN: 18793142     Source Type: Journal    
DOI: 10.1016/j.trac.2013.12.006     Document Type: Review

References (159)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA. Cancer J. Clin. 2010, 60:277-300.
2. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D.B. Cancer Incidence in Five Continents 2002, IARC Scientific Publications, No. 155 Lyon, IARC.
3. Jacques, Ferlay, Hai-Rim, Bray, Freddie, Forman, David, Mathers, Colin, Parkin, Maxwell Donald Globocan 2008 2010, Cancer Incidence and Mortality Worldwide.
4. Alexandre M., Pandol S.J., Gorelick F.S., Thrower E.C. The emerging role of smoking in the development of pancreatitis. Pancreatol. Off. J. Int. Assoc. Pancreatol. IAP Al 2011, 11:469-474.
5. Herreros-Villanueva M., Hijona E., Bañales J.M., Cosme A., Bujanda L. Alcohol consumption on pancreatic diseases. World J. Gastroenterol. WJG 2013, 19:638-647.
6. Morrison M. PC and diabetes. Adv. Exp. Med. Biol. 2012, 771:229-239.
7. Vucenik I., Stains J.P. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann. NY Acad. Sci. 2012, 1271:37-43.
8. Trikudanathan G., Philip A., Dasanu C.A., Baker W.L. Association between Helicobacter pylori infection and PC. A cumulative meta-analysis. JOP J. Pancreas. 2011, 12:26-31.
9. Wolpin B.M., Chan A.T., Hartge P., Chanock S.J., Kraft P., Hunter D.J., et al. ABO blood group and the risk of PC. J. Natl. Cancer Inst. 2009, 101:424-431.
10. Iodice S., Maisonneuve P., Botteri E., Sandri M.T., Lowenfels A.B. ABO blood group and cancer. Eur. J. Cancer Oxf. Engl. 2010, 1990(46):3345-3350.
11. Pelzer U., Klein F., Bahra M., Sinn M., Dörken B., Neuhaus P., et al. Blood group determinates incidence for PC in Germany. Front. Physiol. 2013, 4:118.
12. Kuvshinoff B.W., Bryer M.P. Treatment of resectable and locally advanced PC. Cancer Control J. Moffitt Cancer Cent. 2000, 7:428-436.
13. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 2012, 62:10-29.
14. Pannala R., Basu A., Petersen G.M., Chari S.T. New-onset diabetes: a potential clue to the early diagnosis of PC. Lancet Oncol. 2009, 10:88-95.
15. Wray C.J., Ahmad S.A., Matthews J.B., Lowy A.M. Surgery for PC: recent controversies and current practice. Gastroenterology 2005, 128:1626-1641.
16. Brand R.E., Matamoros A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig. Dis. Basel Switz. 1998, 16:242-252.
17. Oettle H., Neuhaus P. Adjuvant therapy in PC: a critical appraisal. Drugs 2007, 67:2293-2310.
18. Carmichael J., Fink U., Russell R.C., Spittle M.F., Harris A.L., Spiessi G., et al. Phase II study of gemcitabine in patients with advanced PC. Br. J. Cancer. 1996, 73:101-105.
19. Jordheim L.P., Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta. 2007, 1776:138-159.
20. Ohmine K., Kawaguchi K., Ohtsuki S., Motoi F., Egawa S., Unno M., et al. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a PC cell line: targeted proteomic and metabolomics analyses in PK9 cells. Pharm. Res. 2012, 29:2006-2016.
21. Frebourg T., Bercoff E., Manchon N., Senant J., Basuyau J.P., Breton P., et al. The evaluation of CA 19-9 antigen level in the early detection of PC. A prospective study of 866 patients. Cancer 1988, 62:2287-2290.
22. Goonetilleke K.S., Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of PC. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2007, 33:266-270.
23. Gold D.V., Modrak D.E., Ying Z., Cardillo T.M., Sharkey R.M., Goldenberg D.M. New MUC1 serum immunoassay differentiates PC from pancreatitis. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006, 24:252-258.
24. Armitage E.G., Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J. Pharm. Biomed. Anal. 2014, 87:1-11.
25. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002, 1:153-161.
26. Fiehn O., Kopka J., Dörmann P., Altmann T., Trethewey R.N., Willmitzer L. Metabolite profiling for plant functional genomics. Nat. Biotechnol. 2000, 18:1157-1161.
27. Davis V.W., Bathe O.F., Schiller D.E., Slupsky C.M., Sawyer M.B. Metabolomics and surgical oncology: Potential role for small molecule biomarkers. J. Surg. Oncol. 2011, 103:451-459.
28. Ocaña A., Pandiella A. Personalized therapies in the cancer "omics" era. Mol. Cancer. 2010, 9:202.
29. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 1999, 340:1330-1340.
30. Zhang A.-H., Sun H., Qiu S., Wang X.-J. Metabolomics in noninvasive breast cancer. Clin. Chim. Acta Int. J. Clin. Chem. 2013, 424C:3-7.
31. Zhang T., Wu X., Ke C., Yin M., Li Z., Fan L., et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomics profiling. J. Proteome Res. 2013, 12:505-512.
32. Wettersten H.I., Weiss R.H. Applications of Metabolomics for Kidney Disease Research: From biomarkers to therapeutic targets. Organogenesis 2013, 9:11-18.
33. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 2007, 26:51-78.
34. Dudley E., Yousef M., Wang Y., Griffiths W.J. Targeted metabolomics and mass spectrometry. Adv. Protein Chem. Struct. Biol. 2010, 80:45-83.
35. Krastanov A. Metabolomics - The State of Art. Biotechnol. Biotechnol. Equip. 2010, 24:1537-1543.
36. Lindon J.C., Holmes E., Nicholson J.K. So what's the deal with metabonomics?. Anal. Chem. 2003, 75:384A-391A.
37. Beckonert O., Keun H.C., Ebbels T.M.D., Bundy J., Holmes E., Lindon J.C., et al. Metabolic profiling, metabolomics and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2:2692-2703.
38. Castle A.L., Fiehn O., Kaddurah-Daouk R., Lindon J.C. Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results. Brief. Bioinform. 2006, 7:159-165.
39. 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J. Pharm. Biomed. Anal. 2003, 33:1103-1115.
40. Reo N.V. NMR-based metabolomics. Drug Chem. Toxicol. 2002, 25:375-382.
41. Kobayashi T., Nishiumi S., Ikeda A., Yoshie T., Sakai A., Matsubara A., et al. A novel serum metabolomics-based diagnostic approach to PC. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev Oncol. 2013, 22:571-579.
42. Leichtle A.B., Ceglarek U., Weinert P., Nakas C.T., Nuoffer J.-M., Kase J., et al. Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics Off. J. Metabolomic Soc. 2013, 9:677-687.
43. 1H NMR spectroscopy and principal component analysis. Appl. Biochem. Biotechnol. 2011, 165:148-154.
44. Bathe O.F., Shaykhutdinov R., Kopciuk K., Weljie A.M., McKay A., Sutherland F.R., et al. Feasibility of identifying PC based on serum metabolomics. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev Oncol. 2011, 20:140-147.
45. Nishiumi S., Shinohara M., Ikeda A., Yoshie T., Hatano N., Kakuyama S., Mizuno S., Sanuki T., Kutsumi H., Fukusaki E., Azuma T., Takenawa T., Yoshida M. Serum metabolomics as a novel diagnostic approach for PC. Metabolomics 2010, 6:518-528.
46. Davis V.W., Schiller D.E., Eurich D., Bathe O.F., Sawyer M.B. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann. Surg. Oncol. 2012.
47. Napoli C., Sperandio N., Lawlor R.T., Scarpa A., Molinari H., Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J. Proteome Res. 2012, 11:1274-1283.
48. Urayama S., Zou W., Brooks K., Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of PC. Rapid Commun. Mass Spectrom. RCM 2010, 24:613-620.
49. Zhang H., Wang Y., Gu X., Zhou J., Yan C. Metabolomic profiling of human plasma in PC using pressurized capillary electrochromatography. Electrophoresis 2011, 32:340-347.
50. Zhang L., Jin H., Guo X., Yang Z., Zhao L., Tang S., et al. Distinguishing PC from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles. Clin. Biochem. 2012, 45:1064-1069.
51. Zyromski N.J., Mathur A., Gowda G.A.N., Murphy C., Swartz-Basile D.A., Wade T.E., et al. Nuclear magnetic resonance spectroscopy-based metabolomics of the fatty pancreas: implicating fat in pancreatic pathology. Pancreatol. Off. J. Int. Assoc. Pancreatol. IAP Al 2009, 9:410-419.
52. Fang F., He X., Deng H., Chen Q., Lu J., Spraul M., et al. Discrimination of metabolic profiles of PC from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer Sci. 2007, 98:1678-1682.
53. Bezabeh T., Ijare O.B., Albiin N., Arnelo U., Lindberg B., Smith I.C.P. Detection and quantification of D-glucuronic acid in human bile using 1H NMR spectroscopy: relevance to the diagnosis of PC. Magma N Y N 2009, 22:267-275.
54. Longnecker D.S., Chandar N., Sheahan D.G., Janosky J.E., Lombardi B. Preneoplastic and neoplastic lesions in the pancreas of rats fed choline-devoid or choline-supplemented diets. Toxicol. Pathol. 1991, 19:59-65.
55. Ritchie S.A., Akita H., Takemasa I., Eguchi H., Pastural E., Nagano H., et al. Metabolic system alterations in PC patient serum: potential for early detection. BMC Cancer 2013, 13:416.
56. Sugimoto M., Wong D.T., Hirayama A., Soga T., Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and PC-specific profiles. Metabolomics Off. J. Metabolomic Soc. 2010, 6:78-95.
57. Kaur P., Sheikh K., Kirilyuk A., Kirilyuk K., Singh R., Ressom H.W., Cheema A.K. Metabolomic profiling for biomarker discovery in PC. Intern. J. Mass Spec. 2012, 310:44-51.
58. de Almeida P.D.V., Grégio A.M.T., Machado M.A.N., de Lima A.A.S., Azevedo L.R. Saliva composition and functions: a comprehensive review. J. Contemp. Dent. Pract. 2008, 9:72-80.
59. Wen H., Yoo S.S., Kang J., Kim H.G., Park J.-S., Jeong S., et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J. Hepatol. 2010, 52:228-233.
60. Nishijima T., Nishina M., Fujiwara K. Measurement of lactate levels in serum and bile using proton nuclear magnetic resonance in patients with hepatobiliary diseases: its utility in detection of malignancies. Jpn. J. Clin. Oncol. 1997, 27:13-17.
61. Gowda G.A.N. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomark. Med. 2010, 4:299-314.
62. Zhang G., He P., Tan H., Budhu A., Gaedcke J., Ghadimi B.M., et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human PC. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013, 19:4983-4993.
63. Nagrath D., Caneba C., Karedath T., Bellance N. Metabolomics for mitochondrial and cancer studies. Biochim. Biophys. Acta. 1807, 2011:650-663.
64. Werner E., Heilier J.-F., Ducruix C., Ezan E., Junot C., Tabet J.-C. Mass spectrometry for the identification of the discriminating signals from metabolomics: current status and future trends. J. Chromatogr. B. 2008, 871:143-163.
65. Bi H., Krausz K.W., Manna S.K., Li F., Johnson C.H., Gonzalez F.J. Optimization of harvesting, extraction, and analytical protocols for UPLC-ESI-MS-based metabolomics analysis of adherent mammalian cancer cells. Anal. Bioanal. Chem. 2013, 405:5279-5289.
66. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
67. Budczies J., Denkert C., Müller B.M., Brockmöller S.F., Klauschen F., Györffy B., et al. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. BMC Genomics 2012, 13:334.
68. Lindon J.C., Nicholson J.K., Holmes E., Antti H., Bollard M.E., Keun H., et al. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 2003, 187:137-146.
69. Vermeersch K.A., Styczynski M.P. Applications of metabolomics in cancer research. J. Carcinog. 2013, 12:9.
70. 1H NMR-based metabonomics. Nat. Med. 2002, 8:1439-1444.
71. 1H NMR-based metabonomics. Int. J. Cancer J. Int. Cancer. 2005, 113:782-788.
72. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diagn. 2004, 4:189-199.
73. Bhanot U.K., Möller P. Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis: implications for pancreatic carcinogenesis. Lab. Investig. J. Tech. Methods Pathol. 2009, 89:489-497.
74. Beger Richard.D., Schnackenberg Laura.K., Holland Ricky.D., Li Donghui., Dragan Yvonne. Metabonomic models of human PC using 1D proton NMR spectra of lipids in plasma. Metabolomics. 2006, 2:125-134.
75. T. Ikegami, H. Kobayashi, H. Kimura, V. Tolstikov, O. Fiehn, N. Tanaka, High-performance liquid chromatography for metabolomics: high-efficiency separations utilizing mono- lithic silica columns., in: Metabolomics Front. Syst. Biol., Springer-Verlag, Tokyo, 2005: pp. 107-126.
76. Proctor B.L. Recent developments in mass spectrometry for the analysis of complex mixtures. Annu. Rev. Pharmacol. Toxicol. 1983, 23:171-192.
77. Dettmer K., Nürnberger N., Kaspar H., Gruber M.A., Almstetter M.F., Oefner P.J. Metabolite extraction from adherently growing mammalian cells for metabolomics studies: optimization of harvesting and extraction protocols. Anal. Bioanal. Chem. 2011, 399:1127-1139.
78. Zhang A., Sun H., Qiu S., Wang X. NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. Magn. Reson. Chem. MRC 2013, 51:549-556.
79. Wahl H.G., Hoffmann A., Luft D., Liebich H.M. Analysis of volatile organic compounds in human urine by headspace gas chromatography-mass spectrometry with a multipurpose sampler. J. Chromatogr. A. 1999, 847:117-125.
80. Sellick C.A., Hansen R., Stephens G.M., Goodacre R., Dickson A.J. Metabolite extraction from suspension-cultured mammalian cells for global metabolite profiling. Nat. Protoc. 2011, 6:1241-1249.
81. Katajamaa M., Oresic M. Data processing for mass spectrometry-based metabolomics. J. Chromatogr. A. 2007, 1158:318-328.
82. Bijlsma S., Bobeldijk I., Verheij E.R., Ramaker R., Kochhar S., Macdonald I.A., et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal. Chem. 2006, 78:567-574.
83. Trygg J., Holmes E., Lundstedt T. Chemometrics in metabonomics. J. Proteome Res. 2007, 6:469-479.
84. Takahashi N. Three-dimensional mapping of N-linked oligosaccharides using anion-exchange, hydrophobic and hydrophilic interaction modes of high-performance liquid chromatography. J. Chromatogr. A. 1996, 720:217-225.
85. Ge G., Wong G.W. Classification of premalignant PC mass-spectrometry data using decision tree ensembles. BMC Bioinformatics. 2008, 9:275.
86. Leichtle A.B., Dufour J.-F., Fiedler G.M. Potentials and pitfalls of clinical peptidomics and metabolomics. Swiss Med. Wkly. 2013, 143:w13801.
87. Smith C.A., O'Maille G., Want E.J., Qin C., Trauger S.A., Brandon T.R., et al. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 2005, 27:747-751.
88. Kanehisa M., Goto S., Hattori M., Aoki-Kinoshita K.F., Itoh M., Kawashima S., et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006, 34:D354-357.
89. Romero P., Wagg J., Green M.L., Kaiser D., Krummenacker M., Karp P.D. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol. 2005, 6:R2.
90. Frolkis A., Knox C., Lim E., Jewison T., Law V., Hau D.D., et al. SMPDB: the small molecule pathway database. Nucleic Acids Res. 2010, 38:D480-487.
91. Junker B.H., Klukas C., Schreiber F. VANTED: a system for advanced data analysis and visualization in the context of biological networks. BMC Bioinform. 2006, 7:109.
92. Byrnes R.W., Cotter D., Maer A., Li J., Nadeau D., Subramaniam S. An editor for pathway drawing and data visualization in the Biopathways Workbench. BMC Syst. Biol. 2009, 3:99.
93. Merril A.H. SphinGOMAP - a web-based biosynthetic pathway map of sphingolipids and glycosphingolipids. Glycobiology 2005, 15:15G.
94. Yasugi E., Watanabe K. LIPIDBANK for Web, the newly developed lipid database. Tanpakushitsu Kakusan Koso 2002, 47:837-841.
95. Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13:2498-2504.
96. Gao J., Tarcea V.G., Karnovsky A., Mirel B.R., Weymouth T.E., Beecher C.W., et al. Metscape: a Cytoscape plug-in for visualizing and interpreting metabolomics data in the context of human metabolic networks. Bioinforma. Oxf. Engl. 2010, 26:971-973.
97. Karnovsky A., Weymouth T., Hull T., Tarcea V.G., Scardoni G., Laudanna C., et al. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinforma. Oxf. Engl. 2012, 28:373-380.
98. Ma H., Sorokin A., Mazein A., Selkov A., Selkov E., Demin O., et al. The Edinburgh human metabolic network reconstruction and its functional analysis. Mol. Syst. Biol. 2007, 3:135.
99. Baker M. Metabolomics: from small molecules to big ideas. Nat. Meth. 2011, 8:117-121.
100. Kind T., Scholz M., Fiehn O. How large is the metabolome? A critical analysis of data exchange practices in chemistry. PloS One 2009, 4:e5440.
101. Fearon K.C., Barber M.D., Falconer J.S., McMillan D.C., Ross J.A., Preston T. PC as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J. Surg. 1999, 23:584-588.
102. Schrader H., Menge B.A., Belyaev O., Uhl W., Schmidt W.E., Meier J.J. Amino acid malnutrition in patients with chronic pancreatitis and pancreatic carcinoma. Pancreas. 2009, 38:416-421.
103. Yamanouchi T., Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res. Clin. Pract. 1994, 24(Suppl):S261-268.
104. Domínguez-Muñoz J.E. Pancreatic exocrine insufficiency: diagnosis and treatment. J. Gastroenterol. Hepatol. 2011, 26(Suppl 2):12-16.
105. Findeisen P., Neumaier M. Functional protease profiling for diagnosis of malignant disease. Proteomics Clin. Appl. 2012, 6:60-78.
106. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J. Natl. Cancer Inst. 2004, 96:1805-1806.
107. 1H NMR spectroscopy- and mass spectrometry-based metabolomics study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol. Genomics. 2006, 27:178-186.
108. Chan E.C.Y., Koh P.K., Mal M., Cheah P.Y., Eu K.W., Backshall A., et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 2009, 8:352-361.
109. Denkert C., Budczies J., Weichert W., Wohlgemuth G., Scholz M., Kind T., et al. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol. Cancer. 2008, 7:72.
110. Wang J., Ma C., Liao Z., Tian B., Lu J.-P. Study on chronic pancreatitis and PC using MRS and pancreatic juice samples. World J. Gastroenterol. WJG. 2011, 17:2126-2130.
111. 1H NMR spectroscopy. Cancer Biomark. Sect. Dis. Markers 2010, 6:11-20.
112. D.L. Nelson, M.M. Cox, Carbohydrate biosynthesis., in: Lehninger Princ. Biochem., 3rd ed., Worth, New York, 2000: pp. 743-744.
113. Gordon E.R., Goresky C.A., Chang T.H., Perlin A.S. The isolation and characterization of bilirubin diglucuronide, the major bilirubin conjugate in dog and human bile. Biochem. J. 1976, 155:477-486.
114. Sperker B., Werner U., Mürdter T.E., Tekkaya C., Fritz P., Wacke R., et al. Expression and function of beta-glucuronidase in PC: potential role in drug targeting. Naunyn. Schmiedebergs Arch. Pharmacol. 2000, 362:110-115.
115. Clerc P., Bensaadi N., Pradel P., Estival A., Clemente F., Vaysse N. Lipid-dependent proliferation of PC cell lines. Cancer Res. 1991, 51:3633-3638.
116. Dinarello C.A. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006, 25:307-313.
117. Azrad M., Turgeon C., Demark-Wahnefried W. Current evidence linking polyunsaturated fatty acids with cancer risk and progression. Front. Oncol. 2013, 3:224.
118. Algül H., Adler G., Schmid R.M. NF-kappaB/Rel transcriptional pathway: implications in PC. Int. J. Gastrointest. Cancer 2002, 31:71-78.
119. Szlosarek P.W., Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol. 2003, 4:565-573.
120. Ariapart P., Bergstedt-Lindqvist S., van Harmelen V., Permert J., Wang F., Lundkvist I. Resection of PC normalizes the preoperative increase of tumor necrosis factor alpha gene expression. Pancreatol. Off. J. Int. Assoc. Pancreatol. IAP Al 2002, 2:491-494.
121. Pedersen K.S., Bamlet W.R., Oberg A.L., de Andrade M., Matsumoto M.E., Tang H., et al. Leukocyte DNA methylation signature differentiates PC patients from healthy controls. PloS One 2011, 6:e18223.
122. Baine M.J., Menning M., Smith L.M., Mallya K., Kaur S., Rachagani S., et al. Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of PC. Cancer Biomark. Sect. Dis. Markers 2011, 11:1-14.
123. Ren J., Grundy S.M., Liu J., Wang W., Wang M., Sun J., et al. Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis 2010, 211:327-332.
124. Zhang A.Q., Mitchell S.C., Smith R.L. Dimethylamine formation in the rat from various related amine precursors. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 1998, 36:923-927.
125. Brizel D.M., Schroeder T., Scher R.L., Walenta S., Clough R.W., Dewhirst M.W., et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:349-353.
126. Schwickert G., Walenta S., Sundfør K., Rofstad E.K., Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 1995, 55:4757-4759.
127. Walenta S., Chau T.-V., Schroeder T., Lehr H.-A., Kunz-Schughart L.A., Fuerst A., et al. Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists?. J. Cancer Res. Clin. Oncol. 2003, 129:321-326.
128. Baran E.T., Ozer N., Hasirci V. Poly(hydroxybutyrate-co-hydroxyvalerate) nanocapsules as enzyme carriers for cancer therapy: an in vitro study. J. Microencapsul. 2002, 19:363-376.
129. Kim J.M., Song J.S., Cho H.H., Shin K.K., Bae Y.C., Lee B.J., et al. Effect of the modulation of leucine zipper tumor suppressor 2 expression on proliferation of various cancer cells functions as a tumor suppressor. Mol. Cell. Biochem. 2011, 346:125-136.
130. Muddana V., Whitcomb D.C., Khalid A., Slivka A., Papachristou G.I. Elevated serum creatinine as a marker of pancreatic necrosis in acute pancreatitis. Am. J. Gastroenterol. 2009, 104:164-170.
131. Hiraoka N., Ino Y., Sekine S., Tsuda H., Shimada K., Kosuge T., et al. Tumour necrosis is a postoperative prognostic marker for PC patients with a high interobserver reproducibility in histological evaluation. Br. J. Cancer. 2010, 103:1057-1065.
132. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004, 64:4270-4276.
133. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer. 2004, 4:891-899.
134. Tennant D.A., Durán R.V., Boulahbel H., Gottlieb E. Metabolic transformation in cancer. Carcinogenesis 2009, 30:1269-1280.
135. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
136. Rahman L., Voeller D., Rahman M., Lipkowitz S., Allegra C., Barrett J.C., et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004, 5:341-351.
137. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4:551-561.
138. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006, 66:5977-5980.
139. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
140. Hilvo M., Orěsîc M. Regulation of lipid metabolism in breast cancer provides diagnostic and therapeutic opportunities. Clin. Lipidol. 2012, 7:177-188.
141. Saif M.W. Pancreatic neoplasm in 2011, An update. JOP J. Pancreas 2011, 12:316-321.
142. Pandolfi A., Di Pietro N. High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia?. Cardiovasc. Res. 2010, 86:9-11.
143. Farrell J.J., Elsaleh H., Garcia M., Lai R., Ammar A., Regine W.F., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with PC. Gastroenterology 2009, 136:187-195.
144. Borbath I., Verbrugghe L., Lai R., Gigot J.F., Humblet Y., Piessevaux H., et al. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur. J. Cancer Oxf. Engl. 2012, 1990(48):990-996.
145. Santini D., Schiavon G., Vincenzi B., Cass C.E., Vasile E., Manazza A.D., et al. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr. Cancer Drug Targets. 2011, 11:123-129.
146. Pérez-Torras S., García-Manteiga J., Mercadé E., Casado F.J., Carbó N., Pastor-Anglada M., et al. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human PC. Biochem. Pharmacol. 2008, 76:322-329.
147. Lee C., Raffaghello L., Brandhorst S., Safdie F.M., Bianchi G., Martin-Montalvo A., et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 2012, 4:124ra27.
148. Raffaghello L., Lee C., Safdie F.M., Wei M., Madia F., Bianchi G., et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA 2008, 105:8215-8220.
149. Safdie F., Brandhorst S., Wei M., Wang W., Lee C., Hwang S., et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PloS One 2012, 7:e44603.
150. Marchini S., Fruscio R., Clivio L., Beltrame L., Porcu L., Nerini I.F., et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer Oxf. Engl. 2013, 1990(49):520-530.
151. Zhang H.-L., Yang L.-F., Zhu Y., Yao X.-D., Zhang S.-L., Dai B., et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. The Prostate 2011, 71:326-331.
152. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
153. Gysin S., Salt M., Young A., McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
154. Racker E., Resnick R.J., Feldman R. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc. Natl. Acad. Sci. USA 1985, 82:3535-3538.
155. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
156. Vasseur Sophie, Tomasini Richard, Tournaire Roselyne, Iovanna Juan.L. Cancers. Hypoxia Induc. Tumor Metab. Switch Contrib. Pancreat Cancer Aggress 2010, 2:2138-2152.
157. Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in PC. Proc. Natl. Acad. Sci. USA 2010, 107:246-251.
158. Muñoz-Pinedo C., El Mjiyad N., Ricci J.-E. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012, 3:e248.
159. O.D.K. Maddocks, C.R. Berkers, S.M. Mason, L. Zheng, K. Blyth, E. Gottlieb, et al., Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells, Nature. advance online publication (2012).